Issue of Equity

RNS Number : 5908Y
Physiomics PLC
06 December 2017
 

 

Physiomics plc

("Physiomics") or ("the Company")

 

Issue of Equity

 

Physiomics plc announces today that following the receipt of notice of exercise of employee options, 1,768,815 Ordinary Shares of 0.4p each in the Company (the "Options Shares") have now been issued to the following employees at the following exercise prices:

 

Grantee

Number of shares issued

Exercise price per option

Dr J Millen, CEO

484,641

2.5p

Dr C Chassagnole, COO

645,231

3.5p

Dr C Chassagnole, COO

219,880

2.5p

Other staff

96,448

2.5p

Other staff

322,615

3.5p

 

 

Application has been made to admit the Option Shares to trading on AIM, and dealings in the Option Shares are expected to commence on 12th December 2017.

 

Following the issue of the Option Shares, the total holdings of each Director of the Company will be as follows:

 

Dr Paul Harper                   525,707

Dr Jim Millen                     684,641

Dr Christophe Chassagnole   1,017,008

 

Following the issue of the Option Shares, the total number of shares now in issue is 58,785,394 Ordinary Shares with voting rights attached (one vote per Share).  There are no Shares held in treasury. This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Physiomics under the Disclosure and Transparency Rules.



NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

James Millen

2

Reason for the notification

a)

Position/status

Director, CEO

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Physiomics plc

b)

LEI

213800A71DSZ6ABMTQ91

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary share

 

 

GB00BDR6W943

b)

Nature of the transaction

Share Incentive Plan purchase

c)

Price(s) and volume(s)

Price(s)

Volume(s)

2.5p

484,641

d)

Aggregated information

-     Aggregated volume

-     Price

 

484,641

At 2.5p per share

e)

Date of the transaction

6-12-2017

f)

Place of the transaction

XLON, AIM

 



 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Christophe Chassagnole

2

Reason for the notification

a)

Position/status

Director, COO

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Physiomics plc

b)

LEI

213800A71DSZ6ABMTQ91

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary share

 

 

GB00BDR6W943

b)

Nature of the transaction

Share Incentive Plan purchase

c)

Price(s) and volume(s)

Price(s)

Volume(s)

3.5p

645,231

2.5p

219,880

d)

Aggregated information

-     Aggregated volume

-     Price

 

865,111

At 2.5p and 3.5p as shown in table above

e)

Date of the transaction

6-12-2017

f)

Place of the transaction

XLON, AIM


 

 

Enquiries:

 

Physiomics plc                                                  

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

WH Ireland Limited (nomad)

Katy Mitchell, James Sinclair-Ford

+44 (0) 161 832 2174

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

 

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEEALAKEANXFFF

Companies

Physiomics (PYC)
UK 100

Latest directors dealings